A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis.

Alborzi S, Hamedi B, Omidvar A, Dehbashi S, Alborzi S, Alborzi M

Archives of gynecology and obstetrics27 Jul 2010Cited by 54 (Europe PMC)

PMID20661580DOI10.1007/s00404-010-1599-6PepBankPUB-20661580

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In infertile women after endometriosis surgery, pregnancy rates did not differ significantly between triptorelin and letrozole.
In plain wordsIn women after endometriosis surgery, pregnancy rates did not differ significantly between triptorelin and letrozole.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePregnancy rate versus letrozole
Study
n: not reported in source
Comparator
Letrozole
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Measurements
Pregnancy rate
27.5%
triptorelin
Pregnancy rate
23.4%
letrozole
Source sentences
Summary
Pregnancy rate was 23.4% in group 1, 27.5% in group 2, and 28.1% in group 3. The results did not show significant differences among the 3 groups.
1 context sentence(design, population, supporting numbers)
Summary · context
they were divided into 3 groups: group 1 (47 cases) who received letrozole for 2 months, group 2 (40 patients) who were prescribed triptorelin for 2 months and group 3 who were 57 patients in the control group and did not receive any medication.
Report a problemFND-2066158001
02HumanRandomized controlled trialEfficacy outcome
In infertile women after endometriosis surgery, pregnancy rates did not differ significantly between triptorelin and no medication.
In plain wordsIn women after endometriosis surgery, pregnancy rates did not differ significantly between triptorelin and no medication.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePregnancy rate versus no medication
Study
n: not reported in source
Comparator
No medication
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Measurements
Pregnancy rate
27.5%
triptorelin
Pregnancy rate
28.1%
no medication
Source sentences
Summary
Pregnancy rate was 23.4% in group 1, 27.5% in group 2, and 28.1% in group 3. The results did not show significant differences among the 3 groups.
1 context sentence(design, population, supporting numbers)
Summary · context
they were divided into 3 groups: group 1 (47 cases) who received letrozole for 2 months, group 2 (40 patients) who were prescribed triptorelin for 2 months and group 3 who were 57 patients in the control group and did not receive any medication.
Report a problemFND-2066158002
03HumanRandomized controlled trialEfficacy outcome
In infertile women after surgery, endometriosis recurrence did not differ significantly between triptorelin and letrozole.
In plain wordsIn women after surgery, endometriosis recurrence did not differ significantly between triptorelin and letrozole.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeEndometriosis recurrence versus letrozole
Study
n: not reported in source
Comparator
Letrozole
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Measurements
Recurrence rate
5%
triptorelin
Recurrence rate
6.4%
letrozole
Source sentences
Summary
Recurrence rate of endometriosis was 6.4% in group 1, 5% group 2 and 5.3% in group 3, which was not statistically significantly different as well.
1 context sentence(design, population, supporting numbers)
Summary · context
they were divided into 3 groups: group 1 (47 cases) who received letrozole for 2 months, group 2 (40 patients) who were prescribed triptorelin for 2 months and group 3 who were 57 patients in the control group and did not receive any medication.
Report a problemFND-2066158003
04HumanRandomized controlled trialEfficacy outcome
In infertile women after surgery, endometriosis recurrence did not differ significantly between triptorelin and no medication.
In plain wordsIn women after surgery, endometriosis recurrence did not differ significantly between triptorelin and no medication.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeEndometriosis recurrence versus no medication
Study
n: not reported in source
Comparator
No medication
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Measurements
Recurrence rate
5%
triptorelin
Recurrence rate
5.3%
no medication
Source sentences
Summary
Recurrence rate of endometriosis was 6.4% in group 1, 5% group 2 and 5.3% in group 3, which was not statistically significantly different as well.
1 context sentence(design, population, supporting numbers)
Summary · context
they were divided into 3 groups: group 1 (47 cases) who received letrozole for 2 months, group 2 (40 patients) who were prescribed triptorelin for 2 months and group 3 who were 57 patients in the control group and did not receive any medication.
Report a problemFND-2066158004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.